Leerink Partners Maintains Outperform on Veradermics, Raises Price Target to $150
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Leerink Partners analyst Marc Goodman maintains Veradermics (NYSE:MANE) with a Outperform and raises the price target from $135 to $150.
Leerink Partners analyst Marc Goodman maintains Veradermics (NYSE:MANE) with a Outperform and raises the price target from $135 to $150.
